PMC9889818_01
(A) Multiple depigmented facial patches sparing the periorbital areas after 4 months of treatment with anti-IL-17A antibody (ixekizumab). (B) Wood's lamp of depigmented patches on the face showed bluish-white fluorescence, confirming the diagnosis of vitiligo. (C) Achieving 75% repigmentation of vitiligo under normal light and (D) under Wood's lamp after discontinuation of ixekizumab and 3 months of cyclosporine.
fimmu-13-1077681-g001.jpg
PMC9889818_01_fimmu-13-1077681-g001.jpg
f1
However, she experienced skin erythema, burning sensation, and itchiness in the eighth week of treatment, followed by the rapid development of depigmented patches on the face in the fourth month of treatment ( Figure 1A ). Wood's lamp examination showed bluish-whitish fluorescence on the depigmented patches, confirming the diagnosis of vitiligo ( Figure 1B ). Interestingly, her facial vitiligo also repigmented and achieved 75% repigmentation in the third month of treatment ( Figures 1C, D ).